

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

## Humulin R U-500 (human insulin)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Humulin R U-500 (human insulin)	May be subject to quantity limit

### APPROVAL CRITERIA

Requests for Humulin R U-500 (human insulin) may be approved if the following criteria are met:

- I. Individual has a diagnosis of diabetes mellitus; **AND**
- II. Individual requires more than 200 units of U-100 insulin per day.

Humulin R U-500 (human insulin) may **not** be approved for the following:

- I. For use as a continuous subcutaneous infusion.

### Key References:

1. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes - 2019. *Diabetes Care*. 2019;42: S90-S102.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 12, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Garber AJ, Abrahamson MJ, Barzilay JI, et. al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. *Endocrine Practice*. 2019;25:69-100.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
6. McCulloch DK. General principles of insulin therapy in diabetes mellitus. Last updated: September 20, 2019. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: September 28, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
<b>Applicable</b>	X	X	X	X	X	X	X

7. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Last updated: November 14, 2017. Available at <https://www.fda.gov/Drugs/DrugSafety/ucm493244.htm>. Accessed: October 12, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.